Company to host conference call and webcast on Wednesday, March 31 at 8:30 am EDT LYON, France , March 23, 2020 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and year ended

  Initiatives focused on making HIFU procedures broadly accessible to both Medicare and commercially insured patients  LYON, France , March 3, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, announces today that the company has selected

  Record HIFU revenue growth of 50% in the fourth quarter 2020 driven by the sale of eight HIFU devices sold during the quarter Achieved sequential quarterly revenue growth throughout 2020 notwithstanding challenges posed by the ongoing COVID-19 pandemic Company to announce fourth quarter and full

  LYON, France , January 19, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy based therapies, today announced that Marc Oczachowski , President and CEO, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on

Results on 3,329 patients demonstrate significant difference in efficacy in favor of HIFU versus Radical Prostatectomy (RP) HIFU treatment also resulted in meaningful benefits in both urinary and erectile function versus RP showing superior quality of life preservation capability LYON, France ,

  Recaps progress made in 2020 notwithstanding the ongoing COVID-19 pandemic and previews anticipated 2021 milestones LYON, France , January 6, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today issued the following letter to shareholders:

  LYON, France , January 5, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy based therapies, today announced that it will participate in the 10 th  Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021.

Among December deals closed, two major US institutions have purchased Focal On   University of California, San Francisco Medical Center and Cleveland Clinic become latest to adopt Focal One high intensity focused ultrasound (HIFU) technology   Sales include a bundled sale with ExactVuTM as well as

   Final rules establish, for the first time, a Category 1 CPT code and reimbursement to physicians performing ablation of malignant prostate tissue with HIFU in the US Physician reimbursement for HIFU approximately 30% higher than cryotherapy and brachytherapy Hospital reimbursement for HIFU up

  Generated strongest total revenue quarter of 2020 Reported growth in HIFU procedure revenues year-over-year notwithstanding ongoing COVID-19 pandemic Completed sales to renowned healthcare institutions Mount Sinai Health System in New York and Keck Medical Center at the University of Southern